Matt Phipps
Stock Analyst at William Blair
(0.32)
# 3,998
Out of 4,818 analysts
18
Total ratings
28.57%
Success rate
-38.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $0.97 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $11.03 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $20.10 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $14.29 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $8.66 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $5.31 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $8.48 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $48.21 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $4.53 | - | 2 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $32.20 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.61 | - | 1 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.00 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.62 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $118.00 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $42.00 | - | 1 | Apr 8, 2021 |
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.97
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.03
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $20.10
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $14.29
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.66
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.31
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.48
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $48.21
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.53
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $32.20
Upside: -
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.61
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.00
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.62
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $118.00
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $42.00
Upside: -